id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-288733-c51lfwd6	Kavanagh, Oisín	Inhaled Hydroxychloroquine to Improve Efficacy and Reduce Harm in the Treatment of COVID-19	2020-07-15		.txt	text/plain	769	51	55	An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. Chloroquine and hydroxychloroquine (HCQ) were two of the earliest drugs to 33 receive attention as possible repurposable treatment options for COVID-19 3 . Concerns associated with severe side effects 41 are such that the FDA and EMA now formally recommend against taking HCQ for COVIDEffects of chloroquine on 178 viral infections: An old drug against today's diseases? FDA Drug Safety Communication: FDA cautions 199 against use of hydroxychloroquine or chloroquine for COVID-19 outside of the 200 hospital setting or a clinical trial due to risk of heart rhythm problems Optimizing hydroxychloroquine 210 dosing for patients with COVID-19: An integrative modeling approach for effective 211 drug repurposing	./cache/cord-288733-c51lfwd6.txt	./txt/cord-288733-c51lfwd6.txt